JCJames M. Cunningham

James M. Cunningham

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


James M. Cunningham has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • John Misasi

    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA

    3 shared publications
  • Marceline Côté

    Division of Hematology, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts 02115, United States

    3 shared publications
  • Anna Bruchez

    Division of Hematology, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts 02115, United States

    2 shared publications
  • Claire Marie Filone

    Johns Hopkins University Applied Physics Laboratory

    2 shared publications
  • Kartik Chandran

    Division of Hematology, Department of Medicine, Brigham and Women’s Hospital, Boston, 02115, Massachusetts, USA

    2 shared publications
  • Kyungae Lee

    New England Regional Center of Excellence for Biodefense and Emerging Infectious Diseases, Harvard Medical School, Boston, Massachusetts 02115, United States

    2 shared publications

Latest Publications

  • Open Access

    On-Demand Patient-Specific Phenotype-to-Genotype Ebola Virus Characterization

    by Brett F. Beitzel, Sheli R. Radoshitzky, Nicholas Di Paola, Jennifer M. Brannan, David Kimmel, Katie Caviness, Veronica Soloveva, Shuiqing Yu, Elena N. Postnikova, Courtney L. Finch, et al.

    Biosafety, biosecurity, logistical, political, and technical considerations can delay or prevent the wide dissemination of source material containing viable virus from the geographic origin of an outbreak to laboratories involved in developing medical countermeasures (MCMs). However, once virus genome sequence information is available from clinical samples, reverse-genetics systems can be used to generate virus stocks de novo to initiate MCM development. In this study, we developed a reverse-genetics system for natural isolates of Ebola virus (EBOV) variants Makona, Tumba, and Ituri, which have been challenging to obtain. These systems were generated starting solely with in silico genome sequence information and have been used successfully to produce recombinant stocks of each of the viruses for use in MCM testing. The antiviral activity of MCMs targeting viral entry varied depending on the recombinant virus isolate used. Collectively, selecting and synthetically engineering emerging EBOV variants and demonstrating their efficacy against available MCMs will be crucial for answering pressing public health and biosecurity concerns during Ebola disease (EBOD) outbreaks.


  • Biochemical Basis for Increased Activity of Ebola Glycoprotein in the 2013–16 Epidemic

    by May K. Wang, Sun-Young Lim, Soo Mi Lee, James M. Cunningham


  • Inhibition of Ebola Virus Infection: Identification of Niemann-Pick C1 as the Target by Optimization of a Chemical Probe

    by Kyungae Lee, Tao Ren, Marceline Côté, Berahman Gholamreza, John Misasi, Anna Bruchez, James Cunningham

    A high-throughput screen identified adamantane dipeptide 1 as an inhibitor of Ebola virus (EboV) infection. Hit-to-lead optimization to determine the structure–activity relationship (SAR) identified the more potent EboV inhibitor 2 and a photoaffinity labeling agent 3. These antiviral compounds were employed to identify the target as Niemann-Pick C1 (NPC1), a host protein that binds the EboV glycoprotein and is essential for infection. These studies establish NPC1 as a promising target for antiviral therapy.


  • Filoviruses Require Endosomal Cysteine Proteases for Entry but Exhibit Distinct Protease Preferences

    by John Misasi, Kartik Chandran, Jin-Yi Yang, Bryden Considine, Claire Marie Filone, Marceline Côté, Nancy Sullivan, Giulia Fabozzi, Lisa Hensley, James Cunningham

    Filoviruses are enveloped viruses that cause sporadic outbreaks of severe hemorrhagic fever [CDC, MMWR Morb. Mortal. Wkly. Rep. 50:73–77, 2001; Colebunders and Borchert, J. Infect. 40:16–20, 2000; Colebunders et al., J. Infect. Dis. 196(Suppl. 2):S148–S153, 2007; Geisbert and Jahrling, Nat. Med. 10:S110-S121, 2004]. Previous studies revealed that endosomal cysteine proteases are host factors for ebolavirus Zaire (Chandran et al., Science 308:1643–1645, 2005; Schornberg et al., J. Virol. 80:4174–4178, 2006). In this report, we show that infection mediated by glycoproteins from other phylogenetically diverse filoviruses are also dependent on these proteases and provide additional evidence indicating that they cleave GP1 and expose the binding domain for the critical host factor Niemann-Pick C1. Using selective inhibitors and knockout-derived cell lines, we show that the ebolaviruses Zaire and Cote d'Ivoire are strongly dependent on cathepsin B, while the ebolaviruses Sudan and Reston and Marburg virus are not. Taking advantage of previous studies of cathepsin B inhibitor-resistant viruses (Wong et al., J. Virol. 84:163–175, 2010), we found that virus-specific differences in the requirement for cathepsin B are correlated with sequence polymorphisms at residues 47 in GP1 and 584 in GP2. We applied these findings to the analysis of additional ebolavirus isolates and correctly predicted that the newly identified ebolavirus species Bundibugyo, containing D47 and I584, is cathepsin B dependent and that ebolavirus Zaire-1995, the single known isolate of ebolavirus Zaire that lacks D47, is not. We also obtained evidence for virus-specific differences in the role of cathepsin L, including cooperation with cathepsin B. These studies strongly suggest that the use of endosomal cysteine proteases as host factors for entry is a general property of members of the family Filoviridae .


  • Top Cited Papers
    Open Access

    Small molecule inhibitors reveal Niemann–Pick C1 is essential for Ebola virus infection

    by Marceline Côté, John Misasi, Tao Ren, Anna Bruchez, Kyungae Lee, Claire Marie Filone, Lisa Hensley, Qi Li, Daniel Ory, Kartik Chandran, et al.

    The extraordinary virulence of the Ebola and Marburg filoviruses has spurred intensive research into the molecular mechanisms by which they multiply and cause disease. Carette et al. use a genome-wide genetic screen in human cells to identify factors required for entry of Ebola virus. The screen uncovered 67 mutations disrupting all six members of the homotypic fusion and vacuole protein-sorting (HOPS) multisubunit tethering complex, which is involved in the fusion of endosomes to lysosomes, and 39 independent mutations that disrupt the endo/lysosomal cholesterol transporter protein Niemann–Pick C1 (NPC1). Côté et al. report the identification of a novel benzylpiperazine adamantane diamide-derived compound that inhibits EboV infection in cell culture, with NPC1 being the target. The unexpected role for the hereditary disease gene NPC1 in Ebola virus infection may facilitate the development of antifilovirus therapeutics. Ebola virus (EboV) is a highly pathogenic enveloped virus that causes outbreaks of zoonotic infection in Africa. The clinical symptoms are manifestations of the massive production of pro-inflammatory cytokines in response to infection1 and in many outbreaks, mortality exceeds 75%. The unpredictable onset, ease of transmission, rapid progression of disease, high mortality and lack of effective vaccine or therapy have created a high level of public concern about EboV2. Here we report the identification of a novel benzylpiperazine adamantane diamide-derived compound that inhibits EboV infection. Using mutant cell lines and informative derivatives of the lead compound, we show that the target of the inhibitor is the endosomal membrane protein Niemann–Pick C1 (NPC1). We find that NPC1 is essential for infection, that it binds to the virus glycoprotein (GP), and that antiviral compounds interfere with GP binding to NPC1. Combined with the results of previous studies of GP structure and function, our findings support a model of EboV infection in which cleavage of the GP1 subunit by endosomal cathepsin proteases removes heavily glycosylated domains to expose the amino-terminal domain3,4,5,6,7, which is a ligand for NPC1 and regulates membrane fusion by the GP2 subunit8. Thus, NPC1 is essential for EboV entry and a target for antiviral therapy.


  • Open Access

    Receptor-Induced Thiolate Couples Env Activation to Retrovirus Fusion and Infection

    by Jason G Smith, James M Cunningham

    According to current models of retrovirus infection, receptor binding to the surface subunit (SU) of the envelope glycoprotein (Env) triggers a conformational change in the transmembrane subunit (TM) that mediates virus fusion to cell membranes. To understand how this occurs, we investigated the role of the receptor Tva in avian leukosis virus-A (ALV-A) infection. We find that Tva binding induced the formation of a reactive thiolate on Cys38 (Cys38-S−) in SU. Both chemical and genetic inactivation of Cys38-S− completely abrogated ALV fusion and infection. Remarkably, Cys38-S− does not mediate isomerization of the SU-TM disulfide bond and is not required for Tva-induced activation of TM, including pre-hairpin association with membranes and low pH assembly of helical bundles. These findings indicate that, contrary to current models, receptor activation of TM is not sufficient for ALV fusion and infection and that formation of a reactive thiolate is an additional receptor-dependent step. Many pathogenic viruses including retroviruses, ebolavirus, and SARS have adopted similar ways to enter cells. According to current models of infection, the envelope glycoproteins (Env) of these viruses are activated by their encounter with specific receptor proteins on target cells. In this scheme, receptor binding to the glycoprotein surface subunit releases constraints on the intrinsic membrane fusion activity of the transmembrane subunit. New studies summarized in this report have examined the chemical basis for receptor activation of avian retrovirus envelope glycoproteins. They show that receptor binding creates a reactive cysteine thiolate in the surface subunit that is essential for infection. Remarkably, this cysteine thiolate is not required to activate the known steps in infection mediated by the transmembrane subunit, including insertion into the target membrane and assembly into helical bundles. Thus, the receptor-induced cysteine thiolate mediates a key step in infection that is not accounted for by current models of Env function.


  • Top Cited Papers

    Endosomal Proteolysis of the Ebola Virus Glycoprotein Is Necessary for Infection

    by Kartik Chandran, Nancy J. Sullivan, Ute Felbor, Sean P. Whelan, James M. Cunningham

    Ebola virus (EboV) causes rapidly fatal hemorrhagic fever in humans and there is currently no effective treatment. We found that the infection of African green monkey kidney (Vero) cells by vesicular stomatitis viruses bearing the EboV glycoprotein (GP) requires the activity of endosomal cysteine proteases. Using selective protease inhibitors and protease-deficient cell lines, we identified an essential role for cathepsin B (CatB) and an accessory role for cathepsin L (CatL) in EboV GP-dependent entry. Biochemical studies demonstrate that CatB and CatL mediate entry by carrying out proteolysis of the EboV GP subunit GP1 and support a multistep mechanism that explains the relative contributions of these enzymes to infection. CatB and CatB/CatL inhibitors diminish the multiplication of infectious EboV-Zaire in cultured cells and may merit investigation as anti-EboV drugs.